Farsight Bioscience – At the Front of Value Creation · Farsight Bioscience – At the Front of...

Farsight Bioscience – At the Front of Value Creation

Farsight Bioscience is a targeted drug discovery company with the sole focus on identifying, evaluating, acquiring, developing and partnering to achieve the commercialization of Intellectual Property in the area of drug candidates for human therapeutic use. The company has an innovative and unique approach to the marketing of safe and effective drugs at affordable prices. By keeping overhead costs at an absolute minimum, the company identifies and acquires promising and potentially lucrative drug patents within large markets of significant and incessant growth. Initially, the company focuses on solutions for metabolic disorders, such as obesity, inflammatory diseases, such as arthritis, and common cardiovascular conditions. – All of which are ailments of global and increasingly comprehensive nature.

Farsight runs an unusually lean as well as cost- and time-efficient drug development business through the use of outsourcing and strategic partnerships. The Company undertakes promising drug development projects already in progress and exits any research as soon as a commercially viable exit can be found. Its highly skilled and seasoned team incisively pinpoints rewarding opportunities, and as it, to a large extent, is remunerated in the form of company shares, the growth of the company’s market value is further emphasized for the benefit of its entire investor base.

Farsight Bioscience Limited, publicly traded on The Frankfurt Stock Exchange under XPB.F, is an innovative drug discovery and development company focused on large growing markets for drugs that offer the potential to become profitable blockbusters. Based on a lean, cost- and time-efficient business strategy, underpinned by international outsourcing and strategic expert partnerships, Farsight manages to keep overhead costs remarkably low while still providing safe and effective drugs at affordable prices. Braced by its accomplished team, versatile acknowledged network and innovative rewarding approach to the drug market, Farsight intends to take the market by storm and thus maximize shareholder value.

“Farsight operates withinmarkets of huge potential

growth and with the purpose to make a meaningful and life-changing difference for

those struck by agonizing or even fatal disorders...”

Read more on pages 2-3

www.farsightbioscience.com* Please see important notice and disclaimer on the final page of this document

Frankfurt Stock Exchange: XPB.F

Target Markets with Huge Potential

Farsight’s main scope is within disorders of global, ever-increasing and often life-threatening character; diabetes II, obesity, arthritis, high blood pressure and heart failure are among the most common and well-known disorders embraced by Farsight’s target research and portfolio. They all comply with Farsight’s requirements of being large growing markets with an opportunity for the company to make a meaningful and life-changing difference for those struck by agonizing or even fatal disorders.

Farsight is highly specialized within lifestyle-induced metabolic disorders, such as diabetes II and obesity that increasingly constitute a negative impact upon the health of our society as a whole. According to the WHO, an astonishing 246 million presently suffer from diabetes and in 2005, at least 400 million people were suffering from clinical obesity. Atrocious numbers respectively expected to grow to an immense 380 million by 2030 and 700 million by 2015. Needless to say, the global diabetes market is correspondingly expected to grow from $17 billion in 2005 to a staggering $35 billion in 2012, whereas the anti-obesity market in the same period is predicted to increase from $800 million to $3.1 billion in Europe, USA and Japan alone. The financial potential of safe and effective solutions is indisputably hard to miss.

Furthermore, Farsight is at the forefront of fighting autoimmune diseases. These include debilitating, painful and even lethal inflammations, such as arthritis, multiple sclerosis and psoriasis. Similar to metabolic disorders,the market for autoimmune conditions is perpetually growing. In 2007, the global market generated an impres-sive $31.9 billion and is forecasted to reach a total value of $51.0 billion by 2013. This massive growth itself provides vast opportunities for both large established players as well as newcomers to profit by, and the gap is further facilitated by the withdrawal of several major anti-inflammatory drugs. The

benign market continues to eagerly await safe and effective alternatives to existing therapies.

Moreover, Farsight’s team is purposefully developing improved solutions to cardiovascular disorders, the leading cause of death cutting across gender, racial and ethnic groups. Annually, these ailments account for an estimated $300 billion in treatment costs, loss of productivity, disability and death. The most common cardiovascular disorders are high blood pressure, atherosclerosis (thickening of artery walls, often associated with high cholesterol) and downright heart failure. The total worldwide market was a breathtaking $76 billion in 2008, and it is projected to exceed $111 billion by 2015. As few treatment methods manage or reverse symptoms, there is still a significant unmet medical need.

Farsight’s prime advantage is its collective staff’s unprecedented ability to determinedly, effectively and precisely identify and evaluate the potential

of novel undervalued product candidates at a low expense. Exceptionally promising R&D projects are tracked down, meticulously analyzed and –if profitable– acquired by the company for further development, and subsequently significant value creation. This unique ability allows the company to securely and competitively navigate and operate within huge persistently growing markets and rapidly harvest on successful research.

Profound Portfolio

Despite Farsight being a relatively new player in the Biotech field, it already possesses a comparably extensive portfolio. The company has acquired various promising patent applications, and it is continually re-evaluating their prospects in the light of market and product specific developments. Moreover, additional sound projects have been identified and are constantly being monitored and assessed for potential acquisition, including novel exciting research in nano-technology.

In short, the Intellectual Property already owned by the company is comprised by six projects that meet Farsight’s success determinants. Four of those exploit potential treatments for metabolic disorders associated with obesity, one seeks a therapeutic vaccine for type 2-diabetes and impaired glucose tolerance and another is the development of an appetite suppressant. All projects are based on long-term viable therapy rather than temporary quick fix solutions.

When viably and economically sustainable, the targets will be commercialized through milestone payments and

royalty agreements with Big Pharma, who will undertake the further

development and introduction to the market. With widespread in-house expertise, a comprehensive network of internationally acknowledged research partners and an innovative approach to the drug market, Farsight is confident that it will succeed in executing its current and future projects.




Self-evidently, Farsight is not the only warrior fighting metabolic, inflammatory and cardiovascular disorders. Being determined on finding solutions for comprehensive “epidemics” of global nature obviously entails an immense horde of competitors. However, as long as no actual cure is available, there is an underserved market, always in desperate need for better and more efficient solutions.

Traditionally, biotech companies develop new technology from scratch and typically have a preference of undertaking the majority of the costly tasks in-house. As with all drug development, the company often fails and has to start over, and a large portion of the invested proceeds may turn out as wasted.

Farsight’s overall business strategy is to use its wide-ranging biotech expertise to identify and evaluate undervalued projects already in progress and direct its investments. That way, Farsight has the favorable ability to pick and chose from projects that show potential rewarding outlook, hence the investment risk is significantly reduced. Farsight’s focus is on large potential therapeutic markets, proven to be

increasingly growing, thus increasingly lucrative. The Company takes projects from early stage research and, upon adding value through further cost-effective development, it delivers them to large pharmaceutical companies, ensuring the fastest possible transfer of creative ideas into well-founded drug development projects. Additionally, Farsight keeps a watchful eye on the shorter-term opportunities thrown up by the present “credit crunch”. Promising later-stage projects unfortunately experience financial distress, hence high-quality research can be salvaged at reasonably low cost. Farsight is at the prime spot of the drug development value chain. It possesses the unique and rewarding ability to bridge the gap between auspicious academia and small biotech towards Big Pharma.

The staple foundation of Farsight is to contain overhead costs at the absolute minimum, without compromising efficiency, working conditions and quality. To ensure highest possible returns, research is outsourced to cost-efficient Contract Research Organizations in the UK as well as globally to acknowledged and trusted partners. This includes collaborators

in for instance India, where research of highest international quality standards is provided at a fraction of the cost compared to the Western World. Moreover, Farsight’s network encompasses prominent expert specialists in Europe, including in Spain and Denmark. To further cut overhead costs, the Scientific Advisory Board members do not receive salary or consultancy fees, but have accepted Ordinary Shares in lieu of payment. The Directors and senior management receive consultancy fees, which are remarkably low by industry standards. As for Farsight’s investors, the management team members rely on the increase in the value of their existing holdings of shares to reward their continuing work.

Braced by its accomplished team, versatile network and innovative cost-efficient approach to the drug market, Farsight is confident it will succeed in developing effective quality products with high conveyance value and rewarding profit margins for the benefit of Farsight and its share-holders. Its skillful experts are capable of identifying neglected yet auspicious attractive projects and hence – through reasonably small investment – gain substantial profits.

Cost Effective – Premium Quality

Erling Refsum – CEODr. Refsum has extensive experience within the health care sector. With 18 years as a health care analyst for acknowledged Nomura and Yamaichi and various positions as a surgeon (orthopedic, neurosurgery, accident and emergency, general surgery, cardiothoracic and urology surgery), Dr. Refsum has obtained comprehensive knowledge within vast areas of the medical sector, corporate finance and investments.

Peter Alistair Bell – Executive DirectorMr. Bell has a solid background as an entrepreneur in the real estate, telecom and mineral sectors, within which he has held several director positions. He is highly specialized in investments, negotiation and business development. His widespread and thorough experience in various fields of business will be of significant value for Farsight when settling new deals and partnerships.

Graham May – Company SecretaryThrough more than 30 years of experience, Mr. Graham has gained an all-encompassing knowledge within most areas of law. He holds a degree from Cambridge University. His career has taken him from commercial property transaction to 7 years of practicing law in the Cayman Islands in the areas of banking, insurance, trusts and mutual funds. Mr. May will perform all company secretarial functions for Farsight.

World-Class Management and Advisory Teams

Farsight’s versatile management and advisory teams possess more than a century of combined experience within specialized areas highly relevant for the company. Determination, knowledge and common sense comprise the shared characteristics of the members. They are:




Andrew David Miller – ChairmanDr. Miller is an honorary professor at Kings College London in Pharmaceutical Science. His extensive experience includes research at Cambridge University, Harvard University, Imperial College London and various professorships with acknowledged research institutions. Having received several awards and fellowships, and in his capacity as President of the International Society of Cancer Gene Therapy as well as being the driving force behind Foundation for Global Biomedical Solutions, Prof. Miller is a priceless contribution to Farsight’s team.

Dimitris Tsoukalas – ChairmanDr. Tsoukalas has widespread international educational experience within medicine, communication, management and HR. He has served as a Director in the National Health System of Greece, where he personally examined 60,000 cases. Specialized in General and Family Medicine and being member of American Obesity Society, International Academy of Detoxification Specialists, American Holistic Medicine Association and Nutrition for Optimal Health Association, Dr. Tsoukalas puts immeasurable knowledge at Farsight’s disposal.

Farsight is based on an unusually lean, cost- and time-efficient business model, allowing for remarkably low overhead cost, without compromising quality, safety and effectiveness of drugs.

Farsight targets huge unfulfilled markets individually worth hundreds of millions of dollars. The markets in which the com-pany operates are characterized by perpetually significant growth, and the company’s unique structure allows for secure, effective and competitive navigation within these markets.

Farsight has a strong experienced management team with extensive knowledge within major illnesses. In conjunction with its versatile accomplished advisory board and comprehensive network of internationally acknowledged research partners, Farsight is capable of identifying and acquiring neglected yet auspicious attractive projects at a low expense.

Farsight is at the prime spot of value creation. Its accomplished team detects and acquires undervalued or underfunded patents at low cost, adds further value and, when viably and economically sustainable, the projects are delivered to Big Pharma at large profit margins.

Farsight has a widespread outsourcing network of internationally acknowledged Contract Research Organizations in countries, such as India, where research of highest standards is conducted at a fraction of the cost comparably.

Farsight already possesses 6 promising patent applications, that currently are being matured further to add further value.

Farsight has a flexible approach to value creation, allowing for quick response to ever-changing market conditions.Farsight’s advisory board and management team are to a large extent remunerated in company shares, further reducing overhead cost as well as constituting an emphasized focus on share value growth.

Investment Highlights


www.farsightbioscience.com* IMPORTANT NOTICE AND DISCLAIMER: This document is distributed for information purposes only. It is not an offering for the sale of securities, or a solicitation for an offer to buy securities. It is for your confidential use only and may not be reproduced, sold or redistributed without the express written approval of Farsight Bioscience Limited. For a full disclaimer referring to this document, please refer to the appropriate section of the Farsight Bioscience website at www.farsightbioscience.com.

Farsight Bioscience – At the Front of Value Creation · Farsight Bioscience – At the Front of...

Documents

Transcript of Farsight Bioscience – At the Front of Value Creation · Farsight Bioscience – At the Front of...